CorMedix (CRMD) Lags Q4 Earnings Estimates

分组1 - CorMedix reported quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of $0.86 per share, compared to earnings of $0.22 per share a year ago, representing an earnings surprise of -29.07% [1] - The company posted revenues of $128.62 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.03%, and this is a significant increase from year-ago revenues of $31.21 million [2] - CorMedix shares have lost about 38.8% since the beginning of the year, while the S&P 500 has gained 0.4% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.74 on revenues of $111.85 million, and for the current fiscal year, it is $1.30 on revenues of $307.45 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 46% of over 250 Zacks industries, indicating that the industry outlook can materially impact stock performance [8] - CorMedix has a Zacks Rank of 5 (Strong Sell), suggesting that the shares are expected to underperform the market in the near future [6]